Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients

NCT00730535 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

173

Enrollment

OTHER

Sponsor class

Conditions

Overactive Bladder

Interventions

DRUG: Tolterodine
DRUG: Tolterodine
DRUG: Tolterodine 6

Sponsor

KYU-SUNG LEE

Collaborators

[object Object]